{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:19:17Z","timestamp":1790507957210,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) represents a high-risk and somewhat diverse subtype of AML, and substantial confusion exists about the pathologic evaluation needed for diagnosis, which can include the patient\u2019s clinical history, cytogenetic analysis, mutational analysis, and\/or morphologic evaluation. Treatment decisions based on incomplete or untimely pathology reports may result in the suboptimal treatment of patients with AML-MRC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using a PubMed search, diagnosis of and treatment options for AML-MRC were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This article reviews the current diagnostic criteria for AML-MRC, provides guidance on assessments necessary for an AML-MRC diagnosis, summarizes clinical and prognostic features of AML-MRC, and discusses potential therapies for patients with AML-MRC. In addition to conventional chemotherapy, treatment options include CPX-351, a liposomal encapsulation of daunorubicin\/cytarabine approved for treatment of adults with AML-MRC; targeted agents for patients with certain mutations\/disease characteristics; and lower-intensity therapies for less fit patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Given the evolving and complex treatment landscape and the high-risk nature of the AML-MRC population, a clear understanding of the pathology information necessary for AML-MRC diagnosis has become increasingly important to help guide treatment decisions and thereby improve patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaa107","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T19:10:53Z","timestamp":1591902653000},"page":"731-741","source":"Crossref","is-referenced-by-count":37,"title":["Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)"],"prefix":"10.1093","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-9689","authenticated-orcid":false,"given":"Daniel A","family":"Arber","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry P","family":"Erba","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"2020110406312085500_CIT0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"2020110406312085500_CIT0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol."},{"key":"2020110406312085500_CIT0003","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.path.2010.09.012","article-title":"Acute myeloid leukemia with myelodysplasia-related changes: a new definition","volume":"3","author":"Weinberg","year":"2010","journal-title":"Surg Pathol Clin."},{"key":"2020110406312085500_CIT0004","first-page":"404","article-title":"Acute myeloid leukemia with myelodysplasia related changes","volume":"21","author":"Nagy","year":"2017","journal-title":"Atlas Genet Cytogenet Oncol Haematol."},{"key":"2020110406312085500_CIT0005","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol."},{"key":"2020110406312085500_CIT0006","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4149\/neo_2010_06_578","article-title":"Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic","volume":"57","author":"Szotkowski","year":"2010","journal-title":"Neoplasma."},{"key":"2020110406312085500_CIT0007","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ajh.23772","article-title":"Characteristics of acute myeloid leukemia with myelodysplasia-related changes: a retrospective analysis in a cohort of Chinese patients","volume":"89","author":"Xu","year":"2014","journal-title":"Am J Hematol."},{"key":"2020110406312085500_CIT0008","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ajcp\/aqz206","article-title":"Genetic factors in acute myeloid leukemia with myelodysplasia-related changes","volume":"153","author":"Fang","year":"2020","journal-title":"Am J Clin Pathol."},{"key":"2020110406312085500_CIT0009","first-page":"946","article-title":"De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance","volume":"10","author":"Gahn","year":"1996","journal-title":"Leukemia."},{"key":"2020110406312085500_CIT0010","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood."},{"key":"2020110406312085500_CIT0011","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"key":"2020110406312085500_CIT0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1309\/AJCP58RSMFRHLHHH","article-title":"Acute myeloid leukemia with myelodysplasia-related changes","volume":"144","author":"Vardiman","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"2020110406312085500_CIT0013","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/modpathol.2014.160","article-title":"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations","volume":"28","author":"Ohgami","year":"2015","journal-title":"Mod Pathol."},{"key":"2020110406312085500_CIT0014","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ajh.23211","article-title":"Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations","volume":"87","author":"Devillier","year":"2012","journal-title":"Am J Hematol."},{"key":"2020110406312085500_CIT0015","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","article-title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes","volume":"6","author":"Devillier","year":"2015","journal-title":"Oncotarget."},{"key":"2020110406312085500_CIT0016","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/blood-2011-12-395574","article-title":"Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity","volume":"119","author":"Bacher","year":"2012","journal-title":"Blood."},{"key":"2020110406312085500_CIT0017","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system","volume":"113","author":"Weinberg","year":"2009","journal-title":"Blood."},{"key":"2020110406312085500_CIT0018","first-page":"231","article-title":"Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes","volume":"30","author":"Park","year":"2010","journal-title":"Korean J Lab Med."},{"key":"2020110406312085500_CIT0019","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1182\/blood-2010-09-307314","article-title":"The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status","volume":"116","author":"D\u00edaz-Bey\u00e1","year":"2010","journal-title":"Blood."},{"key":"2020110406312085500_CIT0020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.5858\/arpa.2016-0504-CP","article-title":"Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology","volume":"141","author":"Arber","year":"2017","journal-title":"Arch Pathol Lab Med."},{"key":"2020110406312085500_CIT0021","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.path.2013.08.001","article-title":"Challenges in consolidated reporting of hematopoietic neoplasms","volume":"6","author":"Ohgami","year":"2013","journal-title":"Surg Pathol Clin."},{"key":"2020110406312085500_CIT0022","doi-asserted-by":"crossref","first-page":"932","DOI":"10.5858\/arpa.2015-0450-SA","article-title":"Bone marrow synoptic reporting for hematologic neoplasms: guideline from the College of American Pathologists Pathology and Laboratory Quality Center","volume":"140","author":"Sever","year":"2016","journal-title":"Arch Pathol Lab Med."},{"key":"2020110406312085500_CIT0023","doi-asserted-by":"crossref","first-page":"Abstract 4785","DOI":"10.1182\/blood-2018-99-116415","article-title":"Limited FISH testing for MDS-defining cytogenetic abnormalities rapidly identifies patients with newly diagnosed AML eligible for CPX-351","volume":"132","author":"McMahon","year":"2018","journal-title":"Blood."},{"key":"2020110406312085500_CIT0024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOH.0000000000000314","article-title":"Revisiting erythroleukemia","volume":"24","author":"Arber","year":"2017","journal-title":"Curr Opin Hematol."},{"key":"2020110406312085500_CIT0025","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia, Version 3. 2020","author":"National Comprehensive Cancer Network"},{"key":"2020110406312085500_CIT0026","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"key":"2020110406312085500_CIT0027","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/modpathol.2016.206","article-title":"Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis","volume":"30","author":"Fernandez-Pol","year":"2017","journal-title":"Mod Pathol."},{"key":"2020110406312085500_CIT0028","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2020.1719089","article-title":"Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes","volume":"61","author":"Badar","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"2020110406312085500_CIT0029","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1186\/s12885-017-3803-6","article-title":"Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens","volume":"17","author":"Seymour","year":"2017","journal-title":"BMC Cancer."},{"key":"2020110406312085500_CIT0030","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2020.1723016","article-title":"Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1","author":"Nguyen","year":"2020;61:1395-1405","journal-title":"Leuk Lymphoma."},{"key":"2020110406312085500_CIT0031","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/fon-2017-0603","article-title":"CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia","volume":"14","author":"Talati","year":"2018","journal-title":"Future Oncol."},{"key":"2020110406312085500_CIT0032","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk Res."},{"key":"2020110406312085500_CIT0033","volume-title":"Vyxeos (CPX-351) granted approval in the EU for the treatment of therapy-related acute myeloid leukemia or AML-MRC","author":"Umukoro","year":"2018"},{"key":"2020110406312085500_CIT0034","volume-title":"FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia","author":"Food and Drug Administration","year":"2017"},{"key":"2020110406312085500_CIT0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol."},{"key":"2020110406312085500_CIT0036","doi-asserted-by":"crossref","first-page":"Abstract 1425","DOI":"10.1182\/blood-2018-99-111514","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 in a subgroup of older patients with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) enrolled in a phase 3 study","volume":"132","author":"Ryan","year":"2018","journal-title":"Blood."},{"key":"2020110406312085500_CIT0037","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jclinpath-2016-203863","article-title":"Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category","volume":"70","author":"Weinberg","year":"2017","journal-title":"J Clin Pathol."},{"key":"2020110406312085500_CIT0038","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"2020110406312085500_CIT0039","doi-asserted-by":"crossref","DOI":"10.31525\/fda1-ucm574518.htm","volume-title":"FDA approves gemtuzumab ozogamicin for CD33-positive AML","author":"Food and Drug Administration","year":"2017"},{"key":"2020110406312085500_CIT0040","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet."},{"key":"2020110406312085500_CIT0041","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood."},{"key":"2020110406312085500_CIT0042","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood."},{"key":"2020110406312085500_CIT0043","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med."},{"key":"2020110406312085500_CIT0044","doi-asserted-by":"crossref","DOI":"10.31525\/fda1-ucm627045.htm","volume-title":"FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation","author":"Food and Drug Administration","year":"2018"},{"key":"2020110406312085500_CIT0045","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med."},{"key":"2020110406312085500_CIT0046","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."},{"key":"2020110406312085500_CIT0047","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood."},{"key":"2020110406312085500_CIT0048","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"key":"2020110406312085500_CIT0049","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol."},{"key":"2020110406312085500_CIT0050","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"key":"2020110406312085500_CIT0051","doi-asserted-by":"crossref","DOI":"10.31525\/fda1-ucm626494.htm","volume-title":"FDA approves glasdegib for AML in adults age 75 or older or who have comorbidities","author":"Food and Drug Administration","year":"2018"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/154\/6\/731\/34125980\/aqaa107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/154\/6\/731\/34125980\/aqaa107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T11:32:08Z","timestamp":1604489528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/154\/6\/731\/5899448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,8,31]]},"published-print":{"date-parts":[[2020,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaa107","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,8,31]]}}}